Searched for
BART JANSSENS
Global supply lines struggle to clear container backlog after Suez chaosContainer shipping companies, carrying products ranging from mobile phones to designer goods, have been contending for months with disrupti...- India relies on China for 90 per cent of drug raw materialsIndia's acute dependence for key raw materials which are used to make at least 15 essential drugs can affect pharma industry if a situation...
- India needs to step up to be a biopharma major, says Boston Consulting Group"India offers several advantages in R&D, but it's behind," said Bart Janssens, a BCG partner and coauthor of the report.
- Now, Indian pharma companies like Jubilant Group, TCG Life Sciences and Piramal Life Sciences venture to share new drug R&D risksIndian firms need handholding, but there have been times when they were left on their own after being assigned a project.
- 'Indian bio-pharma R&D spending could grow to $25 bn by 2025'India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...
Load More- Now, Indian pharma companies like Jubilant Group, TCG Life Sciences and Piramal Life Sciences venture to share new drug R&D risks